US$ 26.07
foxo4 dri patent FOXO4-DRI Targeted Apoptosis of Senescent Cells
Description
Third-party lab testing and a Certificate of Analysis (COA) are non-negotiable

J Clin Endocrinol Metab 88:49904996

Q5: How about delivery leadtime A:Delivery lead time: As soon as possible

[DOI] [PubMed] [Google Scholar] 56.Iriz E., Iriz A., Take G., Ozgul H., Oktar L., Demirtas H., Helvacioglu F., Arslan M

Furthermore, there are drug interactions, particularly noted among online communities like Longecity, against the concurrent use of FOXO4-DRI with certain compounds such as Rapamycin, Quercetin, corticosteroids, and cortisol, due to potential interactions that might diminish the peptide's senolytic efficacy
